Symbols

CARISMA Therapeutics Stock Soars 150.23% on Investor Optimism

Generated by AI AgentAinvest Pre-Market Radar

Tuesday, Sep 2, 2025 4:11 am ET1min read

CARM--

Aime Summary

- CARISMA Therapeutics' stock surged 150.23% pre-market on Sept 2, 2025, driven by investor optimism.

- Shares rose 120% in after-hours trading to $0.47, despite a 30.98% monthly decline, signaling potential recovery.

- Volatile price swings reflect market focus on the biotech firm's innovative strategies and future prospects.

- Recent gains highlight renewed investor confidence in CARISMA's ability to deliver on its biotechnology promises.

On September 2, 2025, CARISMA TherapeuticsCARM-- experienced a remarkable surge, with its stock price soaring by 150.23% in the pre-market session.

CARISMA Therapeutics' stock price has been on a rollercoaster ride, with significant volatility in recent trading sessions. The company's shares have shown strong performance after hours, rising by 120.0% to $0.47 during Monday's after-hours session. This surge comes despite a 30.98% decline in the past month, indicating a potential turnaround for the biotech firm.

Investors have been closely monitoring CARISMA Therapeutics due to its innovative approach in the biotechnology sector. The company's recent developments and strategic initiatives have sparked interest among market participants, contributing to the stock's recent price movements. The after-hours gains reflect growing optimism about the company's future prospects and its ability to deliver on its promises.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue